Scios Inc.
Overview
Scios goes straight to the heart of the matter. The company, a subsidiary of health care giant Johnson & Johnson, develops treatments targeting cardiovascular disease. Its flagship product Natrecor is an intravenously administered drug approved by the FDA for treating patients with acute heart failure who also experience shortness of breath with minimal activity. When the drug was introduced in 2001, it was the first new treatment for heart failure in more than 14 years. The drug is not without controversy, about both its long-term health effects and the company's marketing of it. Scios maintains the drug is safe and has launched a large clinical trial.
Sample Overview & HistoryKey Numbers from Hoover's UK
Key financials for Scios Inc.
| Company Type | Subsidiary of Johnson & Johnson |
|---|---|
| Fiscal Year-End | December |
Key People from Hoover's UK
Key people and executives for Scios Inc.
| President | James R. Mitchell (Subscribers see complete biographies -- view sample)
|
|---|---|
| VP Finance | Jim Barr |
| VP Corporate Planning and Development | Tao Fu |
Top Competitors from Hoover's UK
Top competitors of Scios Inc.
There are 10 competitors for Scios; see more.
